Related Experiment Video

Updated: Aug 18, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy

Harm C A Graat, Paul I J M Wuisman, Victor W van Beusechem

    Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
    |March 25, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
    11:06

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

    Published on: July 30, 2018

    Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
    08:07

    Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

    Published on: April 12, 2019

    Related Experiment Videos

    Last Updated: Aug 18, 2026

    A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
    07:31

    A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

    Published on: May 3, 2021

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
    11:06

    Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

    Published on: July 30, 2018

    Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
    08:07

    Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

    Published on: April 12, 2019

    Related Concept Videos

    Rous Sarcoma Virus (RSV) and Cancer01:03

    Rous Sarcoma Virus (RSV) and Cancer

    Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
    RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
    Rous Sarcoma Virus (RSV) and Cancer01:03

    Rous Sarcoma Virus (RSV) and Cancer

    Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
    RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

    Articles linked to this work by shared authors, journal, and citation graph.

    Clinical characteristics, anatomical distribution, and diagnostic patterns of simple bone cysts in Japan: an analysis of the Japanese Bone and Soft Tissue Tumor registry.

    International journal of clinical oncology·2026

    Good Quality of Life 3 Decades After Rotationplasty: A Cross-Sectional Study.

    The Journal of bone and joint surgery. American volume·2026

    Clinical features and treatment outcomes of fibrous dysplasia: a report from the Bone and Soft Tissue Tumor Registry in Japan.

    Japanese journal of clinical oncology·2026

    Clinical characteristics and treatment patterns of tenosynovial giant cell tumor in Japan: an analysis of the Japanese bone and soft tissue tumor registry.

    International journal of clinical oncology·2026

    BCOR-CCNB3 fusion-positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up.

    Frontiers in oncology·2026

    CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

    Trials·2026

    FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Multimodal Gene Expression Deep Learning for Predicting Sentinel Lymph Node Macro-metastasis in Early Breast Cancer: Development and Validation in the SCAN-B Cohort.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Senomorphic miR-3155b suppresses the senescence-associated secretory phenotype in therapy-induced senescence.

    Frontiers in cell and developmental biology·2026

    Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?

    Frontiers in pharmacology·2026

    Breaking the ERK1/2 negative feedback loop: avoiding reactivation and acquisition of resistance by ERK1/2 to anti-cancer agents.

    Frontiers in oncology·2026

    Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies.

    Frontiers in immunology·2026

    Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies.

    Frontiers in immunology·2026

    Profiling crystal engineered ligands for targeting treatment resistant androgen receptors.

    Frontiers in pharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us